Bionomics (BNO) Short Interest
Bionomics (ASX:BNO) had 0.12% of shares reported as short positions as of 11 Sept 2023, representing 1,800,000 shares. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Bionomics
Bionomics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel drug candidates for central nervous system (CNS) disorders. Their primary focus is on anxiety, depression, and other neurological conditions, leveraging their proprietary drug discovery platform. The company aims to address significant unmet medical needs through innovative therapeutic approaches, with a lead candidate in late-stage clinical trials.
Short position
Bionomics (ASX:BNO) has 0.12% of its shares on issue reported as short positions as of 11 Sept 2023, or about 1,800,000 shares. Over the past 30 days that figure has risen 0.12 percentage points, and over 90 days it has risen 0.12 percentage points. Its highest recorded short interest was 0.20% in August 2023. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4BNO intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Bionomics
About
website
Be the first to discuss BNO
Start a research thread or post the first pulse update